Walden Group Healthcare M&A Blog

The Walden Group Releases Q3 2023 Strategic Healthcare M&A Report

11/2/2023
The Walden Group is pleased to provide access to its Q3 2023 Strategic Healthcare M&A Report, which includes:  Q3 2023 Market Overview Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q3 2023 Performance of Leading Healthcare Companies Analysis of...
Read More
The Walden Group Releases Q2 2023 Strategic Healthcare M&A Report

08/10/2023
The Walden Group is pleased to provide access to its Q2 2023 Strategic Healthcare M&A Report, which includes:  Q2 2023 Market Overview Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q2 2023 Performance of Leading Healthcare Companies Analysis of...
Read More
The Walden Group Releases Q1 2023 Strategic Healthcare M&A Report

5/02/2023
The Walden Group is pleased to provide access to its Q1 2023 Strategic Healthcare M&A Report, which includes:  Q1 2023 Market Overview Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in Q1 2023 Performance of Leading Healthcare Companies Analysis...
Read More
Werfen Group Buys Immucor for $2b

3/29/2023
Spain-based manufacturer and distributor of diagnostic instruments Werfen has acquired Immucor, a manufacturer of transfusion and transplant diagnostic devices. The acquisition adds platelet detection, diagnostic analyzers, blood monitoring and molecular testing products that help match patients and donors. Deal terms -- $2b. Keywords:...
Read More
The Walden Group Releases 2022 Year-End Strategic Healthcare M&A Report

3/10/2023
The Walden Group is pleased to provide access to its Q4 2022 Strategic Healthcare M&A Report, which includes:  Recent Divestitures and Spin-Offs Diagnostic and Medical Device Deals with Valuations over $100m Noteworthy M&A Deals By Sector Top Deals > $100m in Transaction Value Announced or Closed in 2022 ...
Read More